Literature DB >> 7775945

Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

E Van Cutsem1, R Snoeck, M Van Ranst, P Fiten, G Opdenakker, K Geboes, J Janssens, P Rutgeerts, G Vantrappen, E de Clercq.   

Abstract

Human papillomaviruses (HPV) are associated with benign lesions and show specificity towards the location or tissues that they infect. HPVs are responsible for warts. Among more than 60 different HPV types known to occur in humans, a strong association has been found between types 16 and 18 and cervical cancer, and such an association is also suspected for types 31, 33, 35, 45, 51, 52, and 56. We describe the effects of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC), following local intratumoral injection, in a 69-year-old woman with hypopharyngeal and esophageal papillomatous lesions, polymerase chain reaction (PCR) positive for HPV types 16 and 18, that relapsed after surgery and that also failed to respond to Nd-Yag laser photocoagulation and alpha-interferon treatment (6 x 10(6) U five times a week for 4 weeks followed by three times a week for 2 months). HPMPC was given at 1.25 mg/kg, with a sclerosing needle, through the biopsy channel of a video-endoscope, directly into the tumor, from March until July 1993 at seven different occasions. The first four injections were given at an interval of 1 week at the level of the hypopharynx. The next three injections were given at an interval of 3 to 5 weeks. During the fourth to the seventh session, half of the dose was injected into the hypopharyngeal and the other half into the esophageal tumor. Three further injections of HPMPC were administered at the level of the esophageal tumor in September 1993 with 2-week intervals. After HPMPC treatment, the lesions became smaller and flat until they completely disappeared.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775945     DOI: 10.1002/jmv.1890450221

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir.

Authors:  D Calista; L Riccioni; L Coccia
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

2.  Intralesional Cidofovir application in recurrent laryngeal papillomatosis.

Authors:  Annett Pudszuhn; Cornelia Welzel; Marc Bloching; Kerstin Neumann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-13       Impact factor: 2.503

3.  The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients.

Authors:  Peter Hyckel; Peter Schleier; Astrid Meerbach; Alexander Berndt; Hartwig Kosmehl; Peter Wutzler
Journal:  Med Microbiol Immunol       Date:  2003-04-10       Impact factor: 3.402

4.  Squamous cell papillomatosis of esophagus following placement of a self-expanding metal stent.

Authors:  P J Karras; M Barawi; B Webb; A Michalos
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

5.  Activities of various compounds against murine and primate polyomaviruses.

Authors:  G Andrei; R Snoeck; M Vandeputte; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 6.  In search of a selective antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 7.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 8.  HPV infections and oesophageal cancer.

Authors:  K J Syrjänen
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

9.  Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.

Authors:  Neil D Christensen; Nancy M Cladel; Jiafen Hu; Karla K Balogh
Journal:  Antiviral Res       Date:  2014-06-16       Impact factor: 5.970

10.  Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.

Authors:  Tim De Schutter; Graciela Andrei; Dimitri Topalis; Lieve Naesens; Robert Snoeck
Journal:  BMC Med Genomics       Date:  2013-05-23       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.